Dublin HealthTech MenoPal targets US menopause market
Dublin-based MenoPal has raised €700,000 and is preparing to expand its menopause intelligence platform into the United States, illustrating the commercialisation pathway from Irish HealthTech innovation to international scale.
Dublin HealthTech company MenoPal is preparing to expand into the US menopause market as it develops its platform for turning fragmented symptom, treatment, wearable and clinical data into personalised intelligence for women and clinicians.
Founded in 2024 by Victoria Finlay and Mark Fagan, the company has raised €700,000 and is already live in Ireland and the UK. According to recent coverage, MenoPal plans to enter the US within the next year and aims to be operating across hundreds of clinics by the end of 2027.
The platform is designed to help users and healthcare professionals understand change over time, evaluate treatment response and make better-informed decisions. MenoPal positions its approach around connecting menopause-related data that can otherwise sit across multiple sources, creating a more structured view of symptoms, treatments and outcomes.
For NWCAM2, the story is relevant because it demonstrates another important stage in the innovation journey: moving from product development into commercialisation and international scale. For HealthTech SMEs, technical capability alone is not enough. Companies also need to validate their proposition, build evidence, develop routes into clinical settings and establish a model that can operate consistently across different markets.
MenoPal’s progression also highlights the value of designing for scalability from an early stage. Expanding into a market such as the US brings additional commercial, regulatory, clinical and operational considerations, and requires a company to demonstrate that its technology, data model and service delivery can support growth without compromising quality or user value.
For SMEs developing health and life-sciences technologies, this is a useful example of how a clearly defined unmet need can become the basis for an international growth proposition. Access to specialist expertise, research collaboration and structured innovation support can help companies strengthen the pathway from initial product development through validation, commercial readiness and market expansion.
Original article
Business Post — Dublin healthtech MenoPal targets US menopause market
https://www.businesspost.ie/companies/dublin-healthtech-menopal-targets-us-menopause-market/
Supporting information
New Frontiers — Dublin healthtech MenoPal targets US menopause market
https://www.newfrontiers.ie/news
The Irish Times — MenoPal app offers proactive support to women going through menopause